Vivos management to present at 1:30 pm Eastern Time on March 23, 2021 HIGHLANDS RANCH   Colorado, March 1, 2021 HIGHLANDS RANCH, Colo., March 11, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep…

Vivos management to present at 11:30 am Eastern Time on March 16, 2021 HIGHLANDS RANCH   Colorado, March 1, 2021 Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman,…

Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from Sleep Apnea HIGHLANDS RANCH   Colorado, March 8, 2021 Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the opening of…

VivoScore Opens the Door for More Patients to be Diagnosed and Treated for Sleep Apnea HIGHLANDS RANCH   Colorado, February 16, 2021 Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA), today announced the launch…

Obstructive Sleep Apnea is One of the Most Prevalent Diseases in the World, Affecting Approximately 1 Billion People and Contributing to Serious Comorbidities HIGHLANDS RANCH   Colorado, January 29, 2021 Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep…

Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares HIGHLANDS RANCH   Colorado, January 29, 2021 Vivos Therapeutics, Inc. (NASDAQ: VVOS) today announced the closing of its initial public offering of 4,025,000 shares of its common stock. The offering consisted of 3,500,000 shares of…

Obstructive Sleep Apnea is One of the Most Prevalent Diseases in the World, Affecting Approximately 1 Billion People and Contributing to Serious Comorbidities HIGHLANDS RANCH   Colorado, January 5, 2021 Vivos Therapeutics, a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, announced…